Johnson & Johnson
Johnson & Johnson Reports Q2 2025 Results and Raises Outlook
Summary
Johnson & Johnson reported a 5.8% increase in Q2 2025 sales to $23.7 billion, with operational growth of 4.6% and adjusted operational growth of 3.0%. The company reported earnings per share (EPS) of $2.29 and adjusted EPS of $2.77. Johnson & Johnson raised its full-year 2025 sales guidance to $93.4 billion (5.4% growth) and adjusted EPS guidance to $10.85, reflecting strong operational performance and favorable foreign exchange results. Significant new product pipeline progress includes approvals for IMAAVY and priority review for TAR-200. Other notable announcements include positive CHMP opinions for DARZALEX and IMBRUVICA, and FDA approval for IMAAVY.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement